Andrew Vaillant
Replicor Inc., Canada
Title: Nucleic acid polymers: Broad spectrum antiviral agents and their development as the backbone of new antiviral therapies for the treatment of chronic HBV and HBV/HDV infection
Biography
Biography: Andrew Vaillant
Abstract
Nucleic acid polymers (NAPs) are an emerging antiviral technology with broad spectrum activity in a variety of enveloped viruses. Through a novel, sequence independent application of oligonucleotide technology, NAPs are able to interfere with entry and post entry mechanisms in many of the viral infections afflicting humans. The pharmacologic features of NAPs, the mechanistic basis for their broad spectrum antiviral activity and their unique antiviral properties in HBV and HDV infection will be discussed as well as their antiviral effects and ability to synergize with immunotherapy to achieve functional control of infection in completed and ongoing clinical trials in patients with chronic HBV infection and HBV/HDV co-infection.
Speaker Presentations
Speaker PPTs Click Here